Biomechanical Injury Modeling (In-Vitro), Blunt Force Injuries to the Extremities (Cellular Injury Model), Cellular Injury and Post-Cryogenic Recovery, Cellular Regeneration and Repair, Cold-Induced Cellular Injury, Cryogenic Cellular Stress, Hypothermic Tissue Stress, Osmotic Stress Injury, Post-Thaw Viability Impairment, Thermal Injury Response, Tissue Damage and Recovery Pathways
Conditions
Keywords
Cryogenics, Cryopreservation, Freeze-Thaw Damage, Cellular Injury, Thermal Injury, Blunt Force Extremity Injury Model, In-Vitro Damage Response, Post-Thaw Regeneration, Osmotic Stress, Tissue Repair Pathways
Brief summary
This laboratory-based study evaluates the effects of controlled cryogenic preservation on human cell samples using Truway Health's in-vitro cryo therapeutic methodology. The study analyzes post-thaw viability, functional recovery, and morphological integrity following exposure to different cryopreservation parameters. Findings will support optimization of cryogenic protocols intended for future translational, biobanking, and therapeutic applications.
Detailed description
Cryogenic preservation plays a central role in cellular therapy, long-term biological storage, regenerative medicine, and advanced manufacturing of therapeutic cell lines. This study investigates how varying cooling rates, cryoprotectant concentrations, and thaw-recovery procedures influence viability and functionality in human-derived cell samples. The intervention consists of laboratory-controlled freeze-thaw cycles at temperatures ranging from -80 °C to -196 °C under defined standard and experimental conditions. Post-thaw evaluations include viability assays, growth kinetics, apoptotic markers, metabolic profiling, and structural assessment. The study is non-clinical and does not involve living human subjects. All cell materials are obtained under appropriate consent or supplied as commercially available research-grade lines.
Interventions
OTHERStandard Laboratory Cryopreservation Procedure
Controlled-rate freezing of human-derived cell samples using an industry-standard cryoprotectant solution (10% dimethyl sulfoxide \[DMSO\] in culture medium) and defined cooling curves, followed by liquid nitrogen vapor storage and rapid rewarming. This intervention is conducted entirely in vitro for laboratory evaluation purposes only.
OTHEREnhanced Laboratory Cryopreservation Procedure
Modified in-vitro cryopreservation process incorporating alternative cryoprotectant formulations, optimized cooling rates, staged thawing procedures, and post-thaw recovery media adjustments. This protocol is investigational in nature but used solely for laboratory research and comparative performance assessment of cell preservation methods.
OTHERNormothermic Cell Culture Control
Cells are cultured continuously under standard laboratory conditions without cryogenic exposure. No cryoprotectants, freezing, or thawing procedures are applied.
Sponsors
Truway Health, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
This is an in-vitro laboratory protocol with no human participants. All interventions are openly assigned to specimen groups; therefore, no masking is required.
Intervention model description
Parallel assignment of human-derived cell samples into multiple intervention groups, including standard cryogenic freeze-thaw protocol, enhanced cryo-therapeutic protocol, and normothermic control. Each group is processed independently and concurrently to evaluate post-thaw viability, cellular injury response, and functional recovery.
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* This study does not enroll human participants. Eligibility applies only to human-derived cell samples. * Samples must be de-identified prior to receipt. * Samples must demonstrate ≥90% viability at pre-freeze assessment. * Samples must be free of contamination (bacterial, fungal, mycoplasma). * Samples must meet chain-of-custody and biospecimen compliance requirements.
Exclusion criteria
* No human participants will be enrolled or contacted. * Any specimen containing identifiable private information. * Samples with inadequate quality, contamination, or compromised viability. * Samples obtained without appropriate donor consent or de-identification certification.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Post-Thaw Viability | Twenty-four (24) hours after thaw | Percentage of viable cells determined by trypan blue exclusion assay or automated cell viability analyzer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cell Proliferation and Long-Term Viability at 7 Days | Seven (7) days after thaw | Cell population doubling time and growth rate calculated from standardized growth curves generated under post-thaw culture conditions. |
| Apoptosis and Necrosis Marker Expression at 24 and 72 Hours | Twenty-four (24) hours and seventy-two (72) hours after thaw | Percentage of cells positive for apoptosis or necrosis markers as determined by Annexin V / Propidium Iodide staining or caspase activity assays. |
| Cellular Metabolic and Functional Integrity from 24 Hours to 7 Days | From twenty-four (24) hours through seven (7) days after thaw | Quantitative assessment of cellular metabolic activity and mitochondrial function using validated metabolic assays (e.g., MTT or resazurin reduction assays), and lineage-specific functional markers where applicable. |
| Morphological Integrity at 24 Hours | Twenty-four (24) hours after thaw | Structural integrity and cellular morphology assessed by phase-contrast microscopy and scored using a predefined morphological grading scale. |
Countries
United States
Outcome results
None listed